Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer. Time to tumor progression, objective response rate, time to confirmed response rate, duration of confirmed response rate, time to treatment failure, and CEA response will be assessed.

本数据集旨在评估卡培他滨（capecitabine）联合厄洛替尼（erlotinib）治疗既往未经治疗的转移性结直肠癌患者的抗肿瘤活性。将对以下指标进行评估：肿瘤进展时间、客观缓解率、至确认缓解的时间、确认缓解持续时间、治疗失败时间以及癌胚抗原（CEA, Carcinoembryonic Antigen）应答情况。